According to filings with the U.S. Securities and Exchange Commission, SciTech Development is raising $3,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Earle Holsapple played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About SciTech Development
SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer treatments. SciTechs innovations and pipeline will impact our mission to develop cost-effective therapeutics that deliver transformative clinical outcomes. Introducing Our Revolutionary New Drug Delivery Platform (SDP) and Lead Cancer Drug Candidate ST-001 nanoFenretinide. Our proprietary Drug Delivery Platform, called SDP, has enormous potential to develop and deliver new and better drugs for incurable cancers. ST-001-nanoFenretinide is our first, patented drug, that combines SDP and the drug fenretinide as a broadly applicable anticancer drug. Fenretinide presents a low-risk scenario as it has been shown to be safe and effective in both children and adults in previous clinical trials. Our immediate goal is to commercialize ST-001 and develop strategic partnerships with companies in the pharmaceutical industry who are looking to expand their existing drug portfolio in oncology, target new diseases, or develop combination drug therapies.

To learn more about SciTech Development, visit http://www.scitechdevelopment.com/

Contact:
Earle Holsapple, Chief Executive Officer
313-263-4887
https://www.linkedin.com/in/earle-holsapple-iii-7837947/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.